BioScience Managers Limited
BioScience Managers is a private, Melbourne-headquartered healthcare-focused funds manager founded in 2003 that invests across life sciences, medical devices, and digital health globally, raising capital from superannuation funds, family offices, and government LPs.
- Company typePrivate
- Founded2003
- HeadquartersMelbourne, Australia
- Headcount11–50
- GTM typeB2B
- OfferingServices
What BioScience Managers Limited does
BioScience Managers Limited (legal entity BioScience Managers Pty Ltd, formerly IB Managers) is a private, Melbourne-headquartered international healthcare investment firm founded in 2003 by Jeremy Curnock Cook, former head of the Biosciences Unit at Rothschild Asset Management. The firm operates as a specialist life sciences funds manager, investing across three pillars — Genomic Medicine, Paediatrics, and Digital Technologies in Healthcare — into private and public companies with biotechnology, medical device, and digital health product profiles globally. Its portfolio spans more than a dozen named companies including Acrux, Adherium, Calcimedica, Cynata Therapeutics, Saluda Medical, and PKG/Global Kinetics Corporation.
The firm has raised and managed at least five distinct investment vehicles: IB Australian Bioscience Fund I (2008, A$42M), Asia Pacific Healthcare Fund II (2013, A$56M), Ventures Fund I and the Translation Fund (2017), and Ventures Fund II (2023), drawing capital primarily from Australian superannuation funds, family offices, university endowments, and the Australian Federal Government. It operates as a Corporate Authorised Representative of Phillip Asset Management Limited within the PhillipCapital Group (parent AUM >US$35B, presence in 15 countries) and holds FCA-regulated status in the UK through Sturgeon Ventures LLP.
Revenue derives from management fees and performance fees (carried interest) on funds under management, with disclosed annualised net IRR exceeding 20%. The firm operates from offices in Melbourne, Perth, Singapore, London, Istanbul, Boston, Los Angeles, and Vancouver, with a senior team combining scientific, clinical, and commercialisation backgrounds. Notable exits include Peplin (acquired by Leo Pharma for US$287.5M), Arana Therapeutics (merged with Cephalon), and Biota Holdings (merged to form Vaxart).
BioScience Managers Limited firmographics
Firmographics- Name
- BioScience Managers Limited
- Legal name
- BioScience Managers Pty Ltd
- Website
- http://www.biosciencemanagers.com
- Company type
- Private
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- BioScience Managers is a private, Melbourne-headquartered healthcare-focused funds manager founded in 2003 that invests across life sciences, medical devices, and digital health globally, raising capital from superannuation funds, family offices, and government LPs.
- Ownership category
- akta.pro rank
BioScience Managers Limited industry classification
Industry- Product category
- Healthcare and Life Sciences Fund Management
- NAICS
- Portfolio Management and Investment Advice (523940)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Healthcare & Life Sciences Growth Equity (FSANACAB)
Keywords
Where BioScience Managers Limited is headquartered
LocationHeadquarters
- HQ city
- Melbourne
- HQ country
- Australia
- HQ region
- Oceania
Offices8 records
Markets served
BioScience Managers Limited business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Revenue model
- Funds Management Fees: BioScience Managers generates revenue through management fees and performance fees (carried interest) from managing healthcare-focused investment funds. The firm manages multiple funds including Australian Bioscience Fund I, Asia Pacific Healthcare Fund II, Ventures Fund I, Translation Fund, and Ventures Fund II.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
BioScience Managers Limited product offering
Product offeringCore offering
BioScience Managers is a specialist healthcare-focused fund management firm that raises capital from institutional investors and deploys it into private and public life sciences, biotechnology, medical device, and digital health companies through multiple closed-end investment funds. The firm provides development and commercialisation capital combined with active portfolio management support, leveraging a global network of advisers and industry experts to source, invest in, and exit healthcare innovation deals.
Product overview
BioScience Managers is an international healthcare investment firm that finances and supports innovative science and technology. The company operates as a fund management platform offering multiple investment funds: IB Australian Bioscience Fund I (2008), Asia Pacific Healthcare Fund II (2013), BioScience Managers Ventures Fund I, Translation Fund (2017), and Ventures Fund II (2023). The company also maintains a portfolio of healthcare companies across life sciences, medical devices, and digital health technologies. The funds target both private and public healthcare companies with clear technological and market advantages, focusing on genomic medicine, paediatrics, and digital technologies as core investment pillars.
Differentiator
Problem solved
Functional benefit
Products and services
- IB Australian Bioscience Fund I BioScience Managers' first closed-end healthcare investment fund, raised in 2008 from superannuation funds, university endowment funds, and family offices, focused on Australian-based biotechnology innovation with global healthcare market translation.
- Asia Pacific Healthcare Fund II Second BioScience Managers fund, launched in 2013 with A$56M raised from superannuation and family offices, focused on Asia Pacific healthcare investment opportunities.
- BioScience Managers Ventures Fund I Venture fund raised in 2017 from superannuation and family offices, targeting venture-stage healthcare investment opportunities.
- BioScience Managers Translation Fund Translation-focused fund raised in 2017 from superannuation and family offices, targeting early-stage healthcare innovation translation.
- BioScience Managers Ventures Fund II Fifth and most recent BioScience Managers fund, launched in 2023 and open to new investors, focused on venture investments in healthcare innovation.
Quantifiable outcome
- 20%+ annualised net IRR
- +1 more outcomes
Companies that use BioScience Managers Limited
Customer profileNamed customers13 records
Segments5 records
Ideal customer profiles2 records
BioScience Managers Limited technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
BioScience Managers Limited partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered minor.
- AusBioTechminorAffiliated with AusBioTech, Australia's national peak body for the biotechnology sector, supporting industry connections and visibility.
- Australian Investment Council (AIC)minorAffiliated with the Australian Investment Council, supporting investment industry connections.
- UK BioIndustry Association (UK BIA)minorAffiliated with UK BIA, the UK's national trade association for the bioscience sector.
- ANDHealthminorPartnership with ANDHealth, a non-profit organisation supporting digital health company commercialisation in Australia.
Scale indicators7 records
Recent moves12 records
Expansion highlights5 records
BioScience Managers Limited competitors and assessment
Company assessmentDirect peers
- OrbiMed Advisors: Global healthcare-dedicated investment firm across venture, growth, and public equity strategies. Most directly comparable healthcare-specialist investment manager to BioScience Managers in mandate and fund structure.
- RA Capital Management: US-based healthcare and life sciences focused investment manager with crossover and venture funds. Comparable in being a specialist healthcare-only investment platform serving institutional LPs.
- ARCH Venture Partners: US-based venture firm focused exclusively on early-stage life sciences and physical sciences companies. Directly comparable in its life sciences-only mandate and active portfolio support model.
- Frazier Healthcare Partners: Dedicated healthcare investment firm with both growth and venture strategies. Comparable in offering multiple fund vintages to LPs and being a healthcare-only specialist.
- Brandon Capital Partners: Australian life sciences venture and growth manager, also backed by the Australian Federal Government. Most direct Australian-based peer given shared geography, LP base, and life sciences focus.
- OneVentures: Australian venture and growth firm with dedicated healthcare and biotech funds. Comparable in being an APAC-based healthcare specialist raising from institutional LPs.
- Aisling Capital: US healthcare-dedicated investment firm founded by Dennis Purcell (an Independent Director of BioScience Managers). Comparable mandate and stage focus.
- Sofinnova Partners: European life sciences venture and growth specialist with multiple fund vintages. Comparable in being a healthcare-only specialist serving institutional LPs across geographies.
- Tekla Capital Management: US-based investment manager focused exclusively on healthcare and life sciences public and private equities. Comparable in running dedicated healthcare funds for institutional investors.
Regional players
- CM Capital Investments: Australian deep-tech and life sciences venture investor. Regional peer with overlapping biotech mandate but broader technology focus than BSM's pure healthcare strategy.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
BioScience Managers Limited social profiles
Digital presenceBioScience Managers Limited financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioScience Managers Limited leadership team
Management profileNumber of profiles
Profiles15 records
BioScience Managers Limited funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioScience Managers Limited M&A and investment
M&A and investmentM&A1 record
Investments24 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioScience Managers Limited
What does BioScience Managers Limited do?
BioScience Managers is a specialist healthcare-focused fund management firm that raises capital from institutional investors and deploys it into private and public life sciences, biotechnology, medical device, and digital health companies through multiple closed-end investment funds. The firm provides development and commercialisation capital combined with active portfolio management support, leveraging a global network of advisers and industry experts to source, invest in, and exit healthcare innovation deals.
Is BioScience Managers Limited a public or private company?
BioScience Managers Limited is a private company. It is classified as corporate owned and is currently operating.
When was BioScience Managers Limited founded?
BioScience Managers Limited was founded in 2003. It employs 11 to 50 people.
Where is BioScience Managers Limited based?
BioScience Managers Limited is headquartered in Melbourne, Australia, in the Oceania region.
How does BioScience Managers Limited make money?
One revenue line is on record: funds Management Fees.
Who are BioScience Managers Limited's main competitors?
Direct peers on record are OrbiMed Advisors, RA Capital Management, ARCH Venture Partners, Frazier Healthcare Partners, Brandon Capital Partners, OneVentures, Aisling Capital, Sofinnova Partners and Tekla Capital Management. CM Capital Investments is listed as a regional player.
Does BioScience Managers Limited have an API?
No public API is recorded for BioScience Managers Limited.
What industry is BioScience Managers Limited in?
BioScience Managers Limited's product category is Healthcare and Life Sciences Fund Management. Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity. Its NAICS code is 523940 and its SIC code is 6282.